Literature DB >> 23964113

Antibody-drug conjugates.

Stephen Ornes.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23964113      PMCID： PMC3752232          DOI： 10.1073/pnas.1314120110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  2 in total

1.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

2.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544
  2 in total
  6 in total

Review 1.  Cancer-Associated, Stimuli-Driven, Turn on Theranostics for Multimodality Imaging and Therapy.

Authors:  Xingshu Li; Jihoon Kim; Juyoung Yoon; Xiaoyuan Chen
Journal:  Adv Mater       Date:  2017-03-29       Impact factor: 30.849

2.  Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.

Authors:  Julien Marcoux; Thierry Champion; Olivier Colas; Elsa Wagner-Rousset; Nathalie Corvaïa; Alain Van Dorsselaer; Alain Beck; Sarah Cianférani
Journal:  Protein Sci       Date:  2015-03-31       Impact factor: 6.725

Review 3.  Theranostics based on AIEgens.

Authors:  Dong Wang; Michelle Mei Suet Lee; Wenhan Xu; Ryan Tsz Kin Kwok; Jacky Wing Yip Lam; Ben Zhong Tang
Journal:  Theranostics       Date:  2018-09-09       Impact factor: 11.556

Review 4.  Exploiting protected maleimides to modify oligonucleotides, peptides and peptide nucleic acids.

Authors:  Clément Paris; Omar Brun; Enrique Pedroso; Anna Grandas
Journal:  Molecules       Date:  2015-04-10       Impact factor: 4.411

5.  Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes.

Authors:  Paul R Moody; Edward J Sayers; Johannes P Magnusson; Cameron Alexander; Paola Borri; Peter Watson; Arwyn T Jones
Journal:  Mol Ther       Date:  2015-09-28       Impact factor: 11.454

Review 6.  How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.

Authors:  Mariangela Garofalo; Giovanni Grazioso; Andrea Cavalli; Jacopo Sgrignani
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.